SCHEMBL20162117

SCHEMBL20162117

N#Cc1cc(F)c2c(c1)CCN(C(=O)O)C2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.38
DPP7 Q9UHL4 1/20 0.38
PDE5A O76074 2/20 0.36
HDAC6 Q9UBN7 1/20 0.35
XDH P47989 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
MAPT P10636 1/20 0.35
CYP11B2 P19099 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
AKR1C3 P42330 2/20 0.34
AKR1C1 Q04828 1/20 0.34
CFTR P13569 1/20 0.34
KCNK3 O14649 4/20 0.33
HTR5A P47898 1/20 0.33
FPR1 P21462 2/20 0.33
FPR2 P25090 2/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29118118 0.84 SLC22A12 (0.41) XDHSLC22A12MAPTTAS1R3TAS1R1
SCHEMBL20169983 0.81 ESR2 (0.49) DPP4DPP7
SCHEMBL29574544 0.81 ESR2 (0.49) DPP4DPP7
SCHEMBL19949181 0.81 DPP4 (0.43) DPP4DPP7HDAC6CFTRHTR5A
SCHEMBL29040808 0.78 HDAC6 (0.40) DPP4DPP7HDAC6HTR5AALDH1A1
SCHEMBL25121131 0.77 DRD2 (0.42) ALDH1A1
SCHEMBL25466869 0.76 DRD2 (0.45) MAPTALDH1A1
SCHEMBL29040775 0.75 AKR1C3 (0.52) MAPTAKR1C3AKR1C1
SCHEMBL28369820 0.75 AKR1C3 (0.52) MAPTAKR1C3AKR1C1FPR1FPR2
SCHEMBL29118120 0.74 ALDH1A1 (0.43) XDHMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 CN disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 US disclosed
US-20200268728-A1 DRUG TARGETING CANCER STEM CELL SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-27 US disclosed
EP-3560494-A1 DRUG TARGETING CANCER STEM CELL Sumitomo Dainippon Pharma Co., Ltd. (JP) 2019-10-30 EP disclosed
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294237-B2 Bicyclic heterocyclic amide derivative NR0B1, NR2E1, NR0B2 DPP4 4820/4885DPP7 4781/4885PDE5A 3211/4885
US-11434472-B2 Agent for removing undifferentiated iPS cells SALL4, NR4A2, NES DPP4 1906/4885DPP7 3223/4885PDE5A 4133/4885
US-20200268728-A1 DRUG TARGETING CANCER STEM CELL NR5A1, NR3C1, NR3C2 DPP4 263/4885DPP7 1514/4885PDE5A 4132/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 DPP4 4820/4885DPP7 4781/4885PDE5A 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.